80 related articles for article (PubMed ID: 10739404)
1. Monitoring platelet inhibition during chronic oral platelet glycoprotein IIb/IIIa blockade: are we missing something?
Serebruany VL; McKenzie ME; Levin DJ; Gurbel PA
Thromb Haemost; 2000 Feb; 83(2):356-7. PubMed ID: 10739404
[No Abstract] [Full Text] [Related]
2. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
[TBL] [Abstract][Full Text] [Related]
3. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
Quinn MJ; Cox D; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2000 Nov; 295(2):670-6. PubMed ID: 11046104
[TBL] [Abstract][Full Text] [Related]
4. Monitoring the effects of platelet glycoprotein IIb/IIIa antagonists with a microtiter plate method for detection of platelet aggregation.
Krause S; Scholz T; Temmler U; Lösche W
Platelets; 2001 Nov; 12(7):423-30. PubMed ID: 11674860
[TBL] [Abstract][Full Text] [Related]
5. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.
Storey RF; May JA; Wilcox RG; Heptinstall S
Thromb Haemost; 1999 Oct; 82(4):1307-11. PubMed ID: 10544919
[TBL] [Abstract][Full Text] [Related]
6. GP IIb/IIIa blockade during peripheral artery interventions.
Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH
Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207
[TBL] [Abstract][Full Text] [Related]
7. Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable.
Leebeek FW; Boersma E; Cannon CP; van de Werf FJ; Simoons ML
Eur Heart J; 2002 Mar; 23(6):444-57. PubMed ID: 11863347
[No Abstract] [Full Text] [Related]
8. Platelet GP IIb/IIIa inhibition in unstable angina and non-ST segment elevation MI: application of the ACC/AHA guidelines.
Young JJ; Choo JK; Kereiakes DJ; ;
J Invasive Cardiol; 2003 Feb; 15(2):102-7; quiz 108. PubMed ID: 12556626
[No Abstract] [Full Text] [Related]
9. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
[No Abstract] [Full Text] [Related]
10. Platelet disaggregation: putting time on your side in acute myocardial infarction.
Simon DI; Sakuma M
J Am Coll Cardiol; 2004 Jul; 44(2):324-6. PubMed ID: 15261926
[No Abstract] [Full Text] [Related]
11. The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitor.
Kondo N; Wakayama F; Suzuki Y; Fukui K; Takaya S; Fukuda I
Thromb Res; 2004; 113(5):303-10. PubMed ID: 15183042
[TBL] [Abstract][Full Text] [Related]
12. The in-vitro effect of tirofiban, glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
Ciborowski M; Tomasiak M; Rusak T; Winnicka K; Dobrzycki S
Blood Coagul Fibrinolysis; 2008 Sep; 19(6):557-67. PubMed ID: 18685439
[TBL] [Abstract][Full Text] [Related]
13. A cold start for oral glycoprotein IIb/IIIa antagonists.
Curtin R; Fitzgerald DJ
Eur Heart J; 2000 Dec; 21(24):1992-4. PubMed ID: 11102247
[No Abstract] [Full Text] [Related]
14. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass.
Tabata S; Yamaguchi S; Nagamine H; Tomita S; Arai S; Takemura H; Watanabe G
Eur J Cardiothorac Surg; 2004 Aug; 26(2):289-93. PubMed ID: 15296885
[TBL] [Abstract][Full Text] [Related]
16. Anti-platelet effects of bioactive compounds isolated from the bark of Rhus verniciflua Stokes.
Jeon WK; Lee JH; Kim HK; Lee AY; Lee SO; Kim YS; Ryu SY; Kim SY; Lee YJ; Ko BS
J Ethnopharmacol; 2006 Jun; 106(1):62-9. PubMed ID: 16431050
[TBL] [Abstract][Full Text] [Related]
17. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
Serebruany VL; Malinin AI; O'connor CM; Gurbel PA;
Am Heart J; 2003 Jul; 146(1):91-8. PubMed ID: 12851613
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
Bolognese L
Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
[TBL] [Abstract][Full Text] [Related]
19. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
[TBL] [Abstract][Full Text] [Related]
20. Oral platelet glycoprotein IIb/IIIa inhibitors.
Kereiakes DJ
Coron Artery Dis; 1999 Dec; 10(8):581-94. PubMed ID: 10599537
[No Abstract] [Full Text] [Related]
[Next] [New Search]
